Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease

18 Jan 2023

Abstract excerpt

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5,000,000 cases worldwide. PD pathology is characterized by the accumulation of misfolded α-synuclein, which is thought to play a critical role in the pathogenesis of the disease. Animal models of PD suggest that activation of Abelson tyrosine kinase (c-Abl) plays an essential role in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36652533
DOI: 10.1126/scitranslmed.abp9352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s diseasePMID 36652533Read ↗

c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic PotentialSemantic proximity Read ↗

A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's diseaseSemantic proximity Read ↗

Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.Semantic proximity Read ↗

c-Abl in Neurodegenerative DiseaseSemantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

Dopaminergic Neurodegeneration Induced by Parkinson’s Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase ActivitySemantic proximity Read ↗

Pharmacological PINK1 activation ameliorates Pathology in Parkinson’s Disease modelsSemantic proximity Read ↗

Yeast Reveal a “Druggable” Rsp5/Nedd4 Network that Ameliorates α-Synuclein Toxicity in NeuronsSemantic proximity Read ↗

DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.Semantic proximity Read ↗

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskSemantic proximity Read ↗

Infection and herbicide exposure implicate c-Abl kinase in α-Synuclein Ser129 phosphorylationSemantic proximity Read ↗

Mitoxantrone Hydrochloride Targets APP and LRRK2 to Improve Neurodegeneration in Parkinson’s ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.